echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sinopharm's dual-target RNAi candidate STP707 gets clinical approval in the U.S.

    Sinopharm's dual-target RNAi candidate STP707 gets clinical approval in the U.S.

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    On July 6, Sirnaomics announced that the company's small interfering nucleic acid (siRNA) candidate STP707 clinical trial application has been approved by the US FDA


    RNA interference (RNAi) is a method of silencing genes through double-stranded RNA


    According to the press release, STP707 is a siRNA drug with both anti-tumor and anti-fibrosis effects.


    The overexpression of TGF-β1 and COX-2 play a key regulatory role in tumor formation


    Previously, STP707 has been in preclinical non-human primate studies.


    Note: The original text has been deleted

    Reference materials:

    [1] The RNAi drug candidate STP707 from Sinopharm was approved by the FDA for the phase I clinical IND for the treatment of solid tumors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.